1. Search Result
Search Result
Results for "

Sodium Chloride Cotransporter (NCC)

" in MedChemExpress (MCE) Product Catalog:

391

Inhibitors & Agonists

8

Fluorescent Dyes

31

Biochemical Assay Reagents

26

Peptides

2

Inhibitory Antibodies

32

Natural
Products

13

Recombinant Proteins

14

Isotope-Labeled Compounds

15

Antibodies

12

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-15409
    Empagliflozin
    Maximum Cited Publications
    89 Publications Verification

    BI 10773

    SGLT Infection Metabolic Disease Cancer
    Empagliflozin (BI 107730 is a selective sodium glucose cotransporter-2 (SGLT-2) inhibitor with an IC50 of 3.1 nM for human SGLT-2 .
    Empagliflozin
  • HY-10450
    Dapagliflozin
    65+ Cited Publications

    BMS-512148

    SGLT Metabolic Disease Cancer
    Dapagliflozin (BMS-512148), a new type of agent used to treat diabetes mellitus (DM), is a competitive sodium/glucose cotransporter 2 (SGLT2) inhibitor, which results in excretion of glucose into the urine . Dapagliflozin induces HIF1 expression and attenuates renal IR injury .
    Dapagliflozin
  • HY-17468
    Bumetanide
    15+ Cited Publications

    Ro 10-6338; PF 1593

    NKCC Cardiovascular Disease Metabolic Disease
    Bumetanide (Ro 10-6338; PF 1593), a highly potent loop diuretic, is a Na +-K +-Cl + cotransporter (NKCC) blocker. Bumetanide is a selective NKCC1 inhibitor, but also inhibits NKCC2, with IC50s of 0.68 μM and 4.0 μM for hNKCC1A and hNKCC2A, respectively .
    Bumetanide
  • HY-132609
    Patisiran sodium
    1 Publications Verification

    Small Interfering RNA (siRNA) Transthyretin (TTR) Neurological Disease
    Patisiran sodium is a double-stranded small interfering RNA that targets a sequence within the transthyretin (TTR) messenger RNA. Patisiran sodium specifically inhibits hepatic synthesis of mutant and wild-type TTR. Patisiran sodium can be used for the research of hereditary TTR amyloidosis .
    Patisiran sodium
  • HY-108764
    Mipomersen sodium
    2 Publications Verification

    ISIS 301012

    Apolipoprotein HCV Metabolic Disease
    Mipomersen sodium (ISIS 301012) is an antisense oligonucleotide inhibitor of apolipoprotein B (apoB). Mipomersen has anti-HCV effect and reduces the infectivity of the HCV. Mipomersen sodium can be used for the research of homozygous familial hypercholesterolemia (HoFH) .
    Mipomersen sodium
  • HY-103023
    CLP290
    2 Publications Verification

    Potassium Channel Neurological Disease
    CLP290 is an orally available activator of the neuron-specific K +-Cl - cotransporter KCC2, displays potential for treatment of a wide range of neurological and psychiatric indications. CLP290 can significantly lower blood arginine-vasopressin (AVP) and glucose levels in STZ (HY-13753) rats .
    CLP290
  • HY-147080

    ARC1905

    Complement System Others
    Avacincaptad pegol (ARC1905) sodium is a 40KDa PEG-conjugated aptamer. Avacincaptad pegol sodium targets complement factor 5 (C5), inhibits the cleavage of C5 into C5a and C5b, limits inflammatory stimulation and complement membrane attack complex (MAC), and is used to study age-related macular degeneration (AMD). Avacincaptad pegol sodium limits irregular cell apoptosis by targeting downstream factors in the complement cascade while preserving the early steps of the complement system .
    Avacincaptad pegol sodium
  • HY-N1462
    Atractyloside potassium salt
    4 Publications Verification

    Chloride Channel Autophagy mTOR AMPK Cardiovascular Disease Metabolic Disease Cancer
    Atractyloside potassium salt is a powerful and specific inhibitor of mitochondrial ADP/ATP transport. Atractyloside potassium salt inhibits chloride channels from mitochondrial membranes of rat heart. Atractyloside potassium salt activates autophagy, inhibits ANT2, mTOR and promotes the activation of p-AMPK. Atractyloside potassium salt has anti-cancer effects on non-small cell lung cancer and can inhibit liver steatosis. Atractylodesin potassium salt has nephrotoxicity .
    Atractyloside potassium salt
  • HY-15461
    Ertugliflozin
    5 Publications Verification

    PF-04971729

    SGLT Metabolic Disease
    Ertugliflozin (PF-04971729) is a potent, selective and orally active inhibitor of the sodium-dependent glucose cotransporter 2 (SGLT2), with an IC50 of 0.877 nM for h-SGLT2 . Has the potential for the treatment of type 2 diabetes mellitus .
    Ertugliflozin
  • HY-10449

    TS 071

    SGLT Metabolic Disease
    Luseogliflozin (TS 071) is a potent, selective, orally active sodium-dependent glucose cotransporter (SGLT) 2 inhibitor, with an IC50 of 2.26 nM, about 1765-fold selectivity over SGLT1 (IC50, 3990 nM). Luseogliflozin has the protential for researching type 2 diabetes .
    Luseogliflozin
  • HY-B0493
    Niflumic acid
    4 Publications Verification

    Chloride Channel COX Inflammation/Immunology Cancer
    Niflumic acid is a calcium-activated chloride channel blocker and COX-2 inhibitor with the IC50 value of 100 nM. Niflumic acid induces apoptosis through caspase-8/Bid/Bax pathway in lung cancer cells. Niflumic acide exhibits anti-tumor activity by affecting the expression of ERK1/2 and the activity of MMP2 and MMP9. Niflumic acid has orally bioactivity. Niflumic acid acts on rheumatoid arthritis .
    Niflumic acid
  • HY-123011

    SHR3824

    SGLT Metabolic Disease
    Henagliflozin (SHR3824) is a potent selective sodium-glucose co-transporter 2 (SGLT2) inhibitor with the IC50 values of 2.38 and 4324 nM for human SGLT2 and SGLT1, respectively. Henagliflozin can be used in diabetes research .
    Henagliflozin
  • HY-109144

    DWP-16001

    SGLT Metabolic Disease
    Enavogliflozin (DWP-16001), an antidiabetic agent, is an orally active, best-in-class and selective sodium-glucose cotransporter-2 (SGLT-2) inhibitor .
    Enavogliflozin
  • HY-14945

    GSK189075

    SGLT Metabolic Disease
    Remogliflozin etabonate (GSK189075) is an orally active, selective and low-affinity sodium glucose cotransporter (SGLT2) inhibitor with Ki values of 1.95 μM, 2.14 μM, 43.1 μM, 8.57 μM for hSGLT2, rSGLT2, hSGLT1, rSGLT1, respectively. Remogliflozin etabonate is a proagent based on benzylpyrazole glucoside and is metabolized to its active form, Remogliflozin, in the body. Remogliflozin etabonate exhibits antidiabetic efficacy in rodent models .
    Remogliflozin etabonate
  • HY-132608

    ISIS-420915 Sodium

    Transthyretin (TTR) Neurological Disease
    Inotersen (ISIS-420915) sodium is a 2′-O-methoxyethyl-modified antisense oligonucleotide. Inotersen sodium inhibits the production of transthyretin (TTR) protein by targeting the TTR RNA transcript and reduces the levels of the TTR transcript. Inotersen sodium can be used for the research of hereditary TTR amyloidosis polyneuropathy .
    Inotersen sodium
  • HY-15461A
    Ertugliflozin L-pyroglutamic acid
    5 Publications Verification

    PF-04971729 L-pyroglutamic acid

    SGLT Metabolic Disease
    Ertugliflozin L-pyroglutamic acid (PF-04971729 L-pyroglutamic acid) is a potent, selective and orally active inhibitor of the sodium-dependent glucose cotransporter 2 (SGLT2), with an IC50 of 0.877 nM for h-SGLT2 . Has the potential for the treatment of type 2 diabetes mellitus .
    Ertugliflozin L-pyroglutamic acid
  • HY-15409R

    BI 10773 (Standard)

    Reference Standards SGLT Metabolic Disease
    Empagliflozin (Standard) is the analytical standard of Empagliflozin. This product is intended for research and analytical applications. Empagliflozin (BI 107730 is a selective sodium glucose cotransporter-2 (SGLT-2) inhibitor with an IC50 of 3.1 nM for human SGLT-2 .
    Empagliflozin (Standard)
  • HY-132613

    Small Interfering RNA (siRNA) Glycolate Oxidase Metabolic Disease
    Lumasiran sodium, an investigational RNA interference (RNAi) therapeutic agent, reduces hepatic oxalate production by targeting glycolate oxidase. Lumasiran sodium reduces urinary oxalate excretion, the cause of progressive kidney failure in primary hyperoxaluria type 1 (PH1) .
    Lumasiran sodium
  • HY-117348

    HDAC Neurological Disease
    NCC-149 is a selective HDAC8 inhibitor and can be used for neural differentiation research .
    NCC-149
  • HY-W134328

    Dextran blue (MW 2000000)

    Biochemical Assay Reagents Others
    Blue dextran (Dextran blue) (MW 2000000) is a high-molecular-weight long-chain polymer of D-glucose. Blue dextran (MW 2000000) serves as an important model macromolecular drug and molecular weight estimation marker, and can be used as a standard for gel permeation chromatography. The release of Blue dextran (MW 2000000) from alginate microspheres is regulated by preparation conditions; its release rate in a pH 6.8 environment is significantly faster than that in pH 1.2, and it exhibits release characteristics close to zero-order kinetics under this condition .
    Blue dextran (MW 2000000)
  • HY-169929

    NKCC Neurological Disease
    KCC2 potentiators-1 (Compound 2) is a Potassium chloride cotransporter-2 (KCC2) potentiator. KCC2 potentiators-1 is promising for research of neurological disorder .
    KCC2 potentiators-1
  • HY-112065
    PF-06869206
    2 Publications Verification

    Sodium Channel Metabolic Disease
    PF-06869206 is an orally bioavailable selective inhibitor of the sodium-phosphate cotransporter NaPi2a (SLC34A1) with an IC50 of 380 nM .
    PF-06869206
  • HY-124738
    BI 01383298
    1 Publications Verification

    Sodium Channel Metabolic Disease
    BI 01383298, a chemical probe, is a potent inhibitor of the sodium-citrate co-transporter (SLC13A5) that is highly expressed in the liver .
    BI 01383298
  • HY-B1477
    Clopamide
    1 Publications Verification

    Sodium Chloride Cotransporter (NCC) Cardiovascular Disease Metabolic Disease
    Clopamide is an orally active thiazide-like diuretic agent that inhibits the sodium-coupled chloride cotransporter SLC12A3. Clopamide has the potential for hypertension and cardiac failure research .
    Clopamide
  • HY-109561

    EYE001; NX1838

    VEGFR Metabolic Disease Inflammation/Immunology
    Pegaptanib sodium is an RNA aptamer with polyethylene glycol modifications, which is directed against vascular endothelial growth factor (VEGF)-165. Pegaptanib could be used for the study of neovascular age-related macular degeneration (AMD) .
    Pegaptanib sodium
  • HY-76562

    Biochemical Assay Reagents Others
    Methyl 6-bromopicolinate is a synthetic intermediate used in the preparation of γ-secretase inhibitor library scaffolds .
    Methyl 6-bromopicolinate
  • HY-69359
    Nipecotic acid
    1 Publications Verification

    (±)-β-Homoproline; Hexahydronicotinic acid; 3-Carboxypiperidine

    GABA Receptor Neurological Disease
    Nipecotic acid ((±)-β-Homoproline) is a potent inhibitor of neuronal and glial-aminobutyric acid (GABA) uptake in vitro. Nipecotic acid can also directly activate GABAA-like chloride channels, with an EC50 of approximately 300 μM .
    Nipecotic acid
  • HY-Z6449

    Adrenergic Receptor Neurological Disease
    Phenylephrine hydrochlorid is an α1-adrenergic receptor agonist. As a sympathomimetic agent, Phenylephrine hydrochlorid exerts similar effects to epinephrine and ephedrine. Phenylephrine hydrochlorid induces vasoconstriction and increases perfusion pressure .
    Phenylephrone hydrochloride
  • HY-15409S

    BI 10773-d4

    SGLT Metabolic Disease
    Empagliflozin-d4 is deuterium labeled Empagliflozin. Empagliflozin (BI 107730 is a selective sodium glucose cotransporter-2 (SGLT-2) inhibitor with an IC50 of 3.1 nM for human SGLT-2 .
    Empagliflozin-d4
  • HY-10450S

    BMS-512148-d5

    Isotope-Labeled Compounds SGLT Metabolic Disease Cancer
    Dapagliflozin-d5 is a deuterium labeled Dapagliflozin (HY-10450). Dapagliflozin is a competitive SGLT2 inhibitor .
    Dapagliflozin-d5
  • HY-N0143A
    Phlorizin dihydrate
    Maximum Cited Publications
    15 Publications Verification

    Floridzin dihydrate

    SGLT PI3K Akt GLUT NF-κB JAK STAT Caspase Apoptosis DNA/RNA Synthesis mTOR Bacterial Infection Neurological Disease Metabolic Disease Cancer
    Phlorizin (Floridzin) dihydrate is an orally active non-selective sodium-glucose cotransporter (SGLT) inhibitor, with an IC50 of 0.04 μM and a Ki of 39 nM against hSGLT2, and an IC50 of 0.17 μM and a Ki of 0.31 μM against hSGLT1. Phlorizin dihydrate promotes GLUT4 translocation, inhibits gluconeogenesis and promotes glycogen synthesis by activating the PI3K/Akt/mTOR pathway. Phlorizin dihydrate reduces DNA damage and apoptosis (apoptosis) by inhibiting the NF-κB inflammatory pathway. Phlorizin dihydrate induces apoptosis via activating the Caspase pathway by antagonizing the JAK/STAT3 and PCK pathways. Phlorizin dihydrate also exhibits antibacterial, anti-inflammatory and neuroprotective activities .
    Phlorizin dihydrate
  • HY-59243
    4,7-Dichloroquinoline
    1 Publications Verification

    Drug Intermediate Others
    4,7-Dichloroquinoline is a dichloro-substituted quinoline that can be used for the synthesis of other active compounds .
    4,7-Dichloroquinoline
  • HY-Y0532
    N-Chlorosuccinimide
    1 Publications Verification

    Succinchlorimide

    Environmental Pollutants Bacterial Infection
    N-Chlorosuccinimide is a five-membered N-containing heterocyclic molecule. N-Chlorosuccinimide is a versatile reagent and can be used for different types of reactions, such as aliphatic and aromatic chlorination. N-Chlorosuccinimide can enhance the antimicrobial effect of Benzalkonium chloride (HY-B2232) on biofilm Pseudomonas aeruginosa .
    N-Chlorosuccinimide
  • HY-B1243
    Propoxycaine hydrochloride
    1 Publications Verification

    Sodium Channel Neurological Disease
    Propoxycaine hydrochloride inhibits voltage-gated sodium channels, and thereby inhibits the ionic flux required for the initiation and conduction of impulses. Propoxycaine hydrochloride application can lead to a loss of sensation.
    Propoxycaine hydrochloride
  • HY-109018
    Velagliflozin
    1 Publications Verification

    SGLT Metabolic Disease
    Velagliflozin is an orally available sodium-glucose cotransporter 2 (SGLT2) inhibitor, with anti-diabetic activity.
    Velagliflozin
  • HY-18172

    Potassium Channel Neurological Disease
    KCC2 blocker 1 is an orally active and selective K +-Cl - cotransporter KCC2 blocker with an IC50 of 1 μM. KCC2 blocker 1 is a benzyl prolinate .
    KCC2 blocker 1
  • HY-14902
    Tofogliflozin
    4 Publications Verification

    CSG452

    SGLT Metabolic Disease
    Tofogliflozin(CSG-452) is a potent and highly specific sodium/glucose cotransporter 2(SGLT2) inhibitor with Ki values of 2.9, 14.9, and 6.4 nM for human, rat, and mouse SGLT2.
    Tofogliflozin
  • HY-128677

    Casein Kinase Neurological Disease
    NCC007 is a dual casein kinase Iα (CKIα) and δ (CKIδ) inhibitor with IC50s of 1.8 and 3.6 μM, respectively. NCC007 can be used in research of modulating mammalian circadian rhythms .
    NCC007
  • HY-W687022A

    Polyvinyl Chloride

    Environmental Pollutants Biochemical Assay Reagents Endocrinology
    Chloroethene polymer (Polyvinyl chloride) is an orally active vinyl chloride polymer. Chloroethene polymer is cytotoxic, reproductively toxic, and an endocrine disruptor. Chloroethene polymer can be used in the research of packaging inner surfaces, food wrapping paper, agricultural crop coverings, and plastic bottles .
    Chloroethene (polymer)
  • HY-106158

    SGLT Metabolic Disease
    T-1095 is a selective and orally active Na +-glucose cotransporter (SGLT) inhibitor with IC50s of 22.8 µM and 2.3 µM for human SGLT1 and SGLT2, respectively. T-1095 can be used for diabetes research .
    T-1095
  • HY-Y0344H

    Halite (Pharmaceutical primary standard, USP)

    Biochemical Assay Reagents Na+/K+ ATPase Interleukin Related Inflammation/Immunology Cancer
    Sodium chloride, United States Pharmacopeia (USP) Reference Standard is an orally active salt. Sodium chloride, United States Pharmacopeia (USP) Reference Standard induces the expression of ATP1A1. Sodium chloride, for cell culture induces the pro-inflammatory cytokines IL-2, TNFα, IL-9 and several chemokines. Sodium chloride, United States Pharmacopeia (USP) Reference Standard enhances the anti-tumor activities of Digoxin (HY-B1049) against small cell lung cancer. Sodium chloride, United States Pharmacopeia (USP) Reference Standard drives autoimmune disease by the induction of pathogenic Th17 cells .
    Sodium chloride, United States Pharmacopeia (USP) Reference Standard
  • HY-10449A

    TS 071 hydrate

    SGLT Metabolic Disease
    Luseogliflozin (TS 071) hydrate is a selective potent and orally active second-generation sodium-glucose co-transporter 2 (SGLT2) inhibitor with an IC50 of 2.26 nM. Luseogliflozin hydrate can be used for the research of type 2 diabetes mellitus (T2DM) .
    Luseogliflozin hydrate
  • HY-117494

    NSC 44626

    Sodium Channel Chloride Channel Cardiovascular Disease
    Flumethiazide (NSC 44626) is an orally active diuretic agent. Flumethiazide has marked diuretic and natruretic effects with significant effects on Sodium, Chloride and water but not on potassium excretion. Flumethiazide can be used for cardiac diseases like essential hypertension research .
    Flumethiazide
  • HY-109542

    Biochemical Assay Reagents Metabolic Disease
    Cyclopenthiazide is a benzothiadiazine diuretic with antihypertensive properties. Cyclopenthiazide exerts a diuretic effect by inhibiting the reabsorption of sodium chloride and water at the distal renal tubules. Cyclopenthiazide increases the excretory capacity of the rat kidney .
    Cyclopenthiazide
  • HY-109092
    Licogliflozin
    1 Publications Verification

    LIK066

    SGLT Metabolic Disease Inflammation/Immunology
    Licogliflozin is a sodium glucose cotransporter (SGLT1 and SGLT2) inhibitor.
    Licogliflozin
  • HY-122369

    Carboxypeptidase Metabolic Disease
    Histargin is a selective carboxypeptidase B inhibitor with an IC50 of 17 μg/mL and a Ki of 30 μM. Histargin exerts competitive inhibition with substrate, with inhibitory activity abolished by metal cations. Histargin shows no significant inhibitory activity against carboxypeptidase A, aminopeptidase A, or aminopeptidase B .
    Histargin
  • HY-13414

    Remogliflozin A

    SGLT Metabolic Disease
    Remogliflozin is a potent and selective inhibitor of SGLT2 (sodium-glucose cotransporter 2) with Kis of 12.4 and 26 nM for human and rat SGLT2, respectively. Remogliflozin is the active form of Remogliflozin etabonate(HY-14945) .
    Remogliflozin
  • HY-Y0537J

    Biochemical Assay Reagents Others
    Potassium chloride, meets analytical specification of Ph. Eur., BP, USP, FCC, E508, ≤0.0001% Al is a neutral potassium salt that can be used for buffer preparation, and can be used in biochemical research .
    Potassium chloride, meets analytical specification of Ph. Eur., BP, USP, FCC, E508, ≤0.0001% Al
  • HY-B0493R

    Reference Standards Chloride Channel COX Inflammation/Immunology
    Niflumic acid (Standard) is the analytical standard of Niflumic acid. This product is intended for research and analytical applications. Niflumic acid is a calcium-activated chloride channel blocker and COX-2 inhibitor with the IC50 value of 100 nM. Niflumic acid induces apoptosis through caspase-8/Bid/Bax pathway in lung cancer cells. Niflumic acide exhibits anti-tumor activity by affecting the expression of ERK1/2 and the activity of MMP2 and MMP9. Niflumic acid has orally bioactivity. Niflumic acid acts on rheumatoid arthritis .
    Niflumic acid (Standard)
  • HY-15461R

    PF-04971729 (Standard)

    Reference Standards SGLT Metabolic Disease
    Ertugliflozin (Standard) is the analytical standard of Ertugliflozin. This product is intended for research and analytical applications. Ertugliflozin (PF-04971729) is a potent, selective and orally active inhibitor of the sodium-dependent glucose cotransporter 2 (SGLT2), with an IC50 of 0.877 nM for h-SGLT2 . Has the potential for the treatment of type 2 diabetes mellitus .
    Ertugliflozin (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: